Complexes of an Alpha Thymosin Derivative with 185/187Re and 99mTc: Structural Analysis and Initial Biological Evaluation

Chemical Biology and Drug Design

Volumn 80, Issue 4, 2012, Pages 545-553

  Benaki, Dimitra ^a   Zikos, Christos ^a   Karachaliou, Chrysoula Evangelia ^a   Tsitsilonis, Ourania ^b   Leondiadis, Leondios ^a   Kalbacher, Hubert ^c   Voelter, Wolfgang ^c   Papadopoulos, Minas ^a   Pirmettis, Ioannis ^a   Pelecanou, Maria ^a   Livaniou, Evangelia ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Alpha thymosins; Immunostimulating peptides; In vivo biodistribution; NMR; Rhenium complexes; Technetium complexes

Indexed keywords

OXYGEN; OXYGEN 18; RHENIUM; TECHNETIUM 99M; THYMOSIN ALPHA1; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHELATION; CIRCULAR DICHROISM; CLINICAL PROTOCOL; COMPLEX FORMATION; CONTROLLED STUDY; DIASTEREOISOMER; DRUG DISTRIBUTION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOTHERAPY; INFLAMMATION; MALE; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; COORDINATION COMPLEXES; ISOMERISM; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MOLECULAR SEQUENCE DATA; RADIOPHARMACEUTICALS; RHENIUM; TECHNETIUM; THYMOSIN;

MUS;

EID: 84866619674     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01425.x     Document Type: Article

References (39)

1. Garaci E. (2007) Thymosin alpha1: a historical overview. Ann N Y Acad Sci;1112:14-20.
2. Goldstein A.L. (2007) History of the discovery of the thymosins. Ann N Y Acad Sci;1112:1-13.
3. Low T.L.K., Thurman G.B., Mcadoo M., Mcclure J., Rossio J.L., Naylor P.H., Goldstein A.L. (1979) Chemistry and biology of thymosin.1. Isolation, characterization, and biological-activities of thymosin-alpha-1 and polypeptide-beta-1 from calf thymus. J Biol Chem;254:981-986.
4. Goldstein A.L., Low T.L.K., Mcadoo M., Mcclure J., Thurman G.B., Rossio J., Lai C.Y., Chang D., Wang S.S., Harvey C., Ramel A.H., Meienhofer J. (1977) Thymosin-alpha-1 - isolation and sequence-analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA;74:725-729.
5. Goldstein A.L., Slater F.D., White A. (1966) Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA;56:1010-1017.
6. Li J., Liu C.H., Wang F.S. (2010) Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides;31:2151-2158.
7. Goldstein A.L., Goldsten A.L. (2009) From lab to bedside: emerging clinical applications of thymosin alpha(1). Expert Opin Biol Ther;9:593-608.
8. Romani L., Bistoni F., Montagnoli C., Gaziano R., Bozza S., Bonifazi P., Zelante T., Moretti S., Rasi G., Garaci E., Puccetti P. (2007) Thymosin alpha 1 - an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci;1112:326-338.
9. Goldstein A.L., Badamchian M. (2004) Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther;4:559-573.
10. Pierluigi B., D'Angelo C., Fallarino F., Moretti S., Zelante T., Bozza S., De Luca A., Bistoni F., Garaci E., Romani L. (2010) Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci;1194:1-5.
11. Naylor P.H., Quadrini K., Garaci E., Rasi G., Hadden J.W. (2007) Immunopharmacology of thymosin alpha 1 and cytokine synergy. Ann N Y Acad Sci;1112:235-244.
12. Romani L., Bistoni F., Gaziano R., Bozza S., Montagnoli C., Perruccio K., Pitzurra L., Bellocchio S., Velardi A., Rasi G., di Francesco P., Garaci E. (2004) Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood;103:4232-4239.
13. Haritos A.A., Goodall G.J., Horecker B.L. (1984) Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Nat Acad Sci USA;81:1008-1011.
14. Freire M., Rey-Mendez M., Gomez-Marquez J., Arias P. (1985) Evidence for the synthesis of thymosin alpha 1 by calf thymocytes and the production of this peptide by natural processing. Arch Biochem Biophys;239:480-485.
15. Sarandeses C.S., Covelo G., Diaz-Jullien C., Freire M. (2003) Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem;278:13286-13293.
16. Baxevanis C.N., Gritzapis A.D., Spanakos G., Tsitsilonis O.E., Papamichail M. (1995) Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha. Cancer Immunol Immunother;40:410-418.
17. Salvin S.B., Horecker B.L., Pan L.X., Rabin B.S. (1987) The effect of dietary zinc and prothymosin alpha on cellular immune responses of RF/J mice. Clin Immunol Immunopathol;43:281-288.
18. Mosoian A., Teixeira A., Burns C.S., Sander L.E., Gusella G.L., He C., Blander J.M., Klotman P., Klotman M.E. (2010) Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc Nat Acad Sci USA;107:10178-10183.
19. Klimentzou P., Beck A., Varvarigou A., Tsitsilonis O., Voelter W., Pirmettis I., Papadopoulos M., Livaniou E., Zikos C. (2007) Solid-phase synthesis of a peptide derivative of thymosin alpha1 and initial studies on its (99m)Tc-radiolabelling. Chem Biol Drug Des;70:40-46.
20. Moody T.W., Fagarasan M., Zia F., Cesnjaj M., Goldstein A.L. (1993) Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res;53:5214-5218.
21. Deutsch E., Libson K., Vanderheyden J.L., Ketring A.R., Maxon H.R. (1986) The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B;13:465-477.
22. Bartholoma M.D., Louie A.S., Valliant J.F., Zubieta J. (2010) Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem Rev;110:2903-2920.
23. Komarek P., Kleisner I., Komarkova I., Konopkova M. (2005) Accumulation of radiolabelled low molecular peptides and proteins in experimental inflammation. Int J Pharm;291:119-125.
24. Wüthrich K. (1986) NMR of Proteins and Nucleic Acids. New York: John-Wiley & Sons, Inc.
25. Wong E., Fauconnier T., Bennett S., Valliant J., Nguyen T., Lau F., Lu L.F.L., Pollak A., Bell R.A., Thornback J.R. (1997) Rhenium(V) and technetium(V) oxo complexes of an N2N'S peptidic chelator: evidence of interconversion between the syn and anti conformations. Inorg Chem;36:5799-5808.
26. Grottesi A., Sette M., Palamara T., Rotilio G., Garaci E., Paci M. (1998) The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy. A possible model for its interaction with the lymphocyte membrane. Peptides;19:1731-1738.
27. Elizondo-Riojas M.A., Chamow S.M., Tuthill C.W., Gorenstein D.G., Volk D.E. (2011) NMR structure of human thymosin alpha-1. Biochem Biophys Res Commun;416:356-361.
28. Adler A.J., Greenfield N.J., Fasman G.D. (1973) Circular dichroism and optical rotatory dispersion of proteins and polypeptides. Methods Enzymol;27:675-735.
29. Gast K., Damaschun H., Eckert K., Schulzeforster K., Maurer H.R., Mullerfrohne M., Zirwer D., Czarnecki J., Damaschun G. (1995) Prothymosin-alpha - a biologically-active protein with random coil conformation. Biochemistry;34:13211-13218.
30. Cantorias M.V., Howell R.C., Todaro L., Cyr J.E., Berndorff D., Rogers R.D., Francesconi L.C. (2007) MO tripeptide diastereomers (M=Tc-99/99m, re): models to identify the structure of Tc-99m peptide targeted radiopharmaceuticals. Inorg Chem;46:7326-7340.
31. Su Z.F., Xu Y. (2008) Possible mechanisms of controlling the configuration, stability, and lipophilicity of [(TcO)-Tc-99m]N3S and [ReO]N3S chelates. J Labelled Compd Radiopharm;51:93-100.
32. Liu S. (2004) The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem Soc Rev;33:445-461.
33. Lee S., Xie J., Chen X. (2010) Peptide-based probes for targeted molecular imaging. Biochemistry;49:1364-1376.
34. Banerjee S.R., Maresca K.P., Francesconi L., Valliant J., Babich J.W., Zubieta J. (2005) New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl Med Biol;32:1-20.
35. Valliant J.F., Riddoch R.W., Hughes D.W., Roe D.G., Fauconnier T.K., Thornback J.R. (2001) The solid phase synthesis and NMR spectroscopy of a Tc-99 chelate-bombesin derived peptide conjugate. Inorg Chim Acta;325:155-163.
36. Wong E., Bennett S., Lawrence B., Fauconnier T., Lu L.F.L., Bell R.A., Thornback J.R., Eshima D. (2001) Tuftsin receptor-binding peptide labeled with technetium: chemistry and preliminary in vitro receptor-binding study. Inorg Chem;40:5695-5700.
37. Cyr J.E., Pearson D.A., Nelson C.A., Lyons B.A., Zheng Y., Bartis J., He J.F., Cantorias M.V., Flowell R.C., Francesconi L.C. (2007) Isolation, characterization, and biological evaluation of syn and anti diastereomers of [Tc-99m]technetium depreotide: a somatostatin receptor binding tumor Imaging agent. J Med Chem;50:4295-4303.
38. Gourni E., Bouziotis P., Benaki D., Loudos G., Xanthopoulos S., Paravatou-Petsotas M., Mavri-Vavagianni M., Pelecanou M., Archimandritis S.C., Varvarigou A.D. (2009) Structural assessment and biological evaluation of two N3S bombesin derivatives. J Med Chem;52:4234-4246.
39. Costopoulos B., Benaki D., Pelecanou M., Mikros E., Stassinopoulou C.I., Varvarigou A.D., Archimandritis S.C. (2004) Structural study by NMR of an oxorhenium-RGD decapeptide complex for application in radiotherapy. Inorg Chem;43:5598-5602.